Xoma to Supply Antibody Agents to SRI International for NIAID Study | GenomeWeb
NEW YORK (GenomeWeb News) — Xoma today said it will create monoclonal antibody agents for SRI International as part of that company’s deal with the National Institute of Allergy and Infectious Disease.
 
Xoma said the firms are still negotiating their contract, which will span 5 years and could be worth as much as $28.1 million. The company added that, if the full contract is awarded it will bring to $60 million the total amount of government contracts it has received since 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.